Clinical Trial

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-15.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT07023588
Lead Sponsor Yehui Tan
Conditions Acute Myeloid Leukemia (AML)
Enrollment 70 participants
Start Date 2025-06-01
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2025-08-08